as 07-26-2024 4:00pm EST
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Founded: | 1992 | Country: | Germany |
Employees: | N/A | City: | N/A |
Market Cap: | 2.8B | IPO Year: | 1999 |
Target Price: | $12.13 | AVG Volume (30 days): | 35.0K |
Analyst Decision: | Hold | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.50 | EPS Growth: | N/A |
52 Week Low/High: | $4.19 - $19.50 | Next Earning Date: | 08-07-2024 |
Revenue: | $264,753,681 | Revenue Growth: | -4.54% |
Revenue Growth (this year): | 3.77% | Revenue Growth (next year): | 24.77% |
MOR Breaking Stock News: Dive into MOR Ticker-Specific Updates for Smart Investing
Business Wire
14 days ago
MT Newswires
a month ago
Business Wire
a month ago
ACCESSWIRE
a month ago
Zacks
2 months ago
BioPharma Dive
2 months ago
Simply Wall St.
3 months ago
Business Wire
3 months ago
The information presented on this page, "MOR MorphoSys AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.